Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject who is free of obvious health problems~* Able and willing to comply with the study procedure adn give written informed consent~Exclusion Criteria:~* Female who is pregnant/lactating or planning to be pregnant~* Body mass index(BMI) \> 35~* Oral temperature \> 37.5 Celsius at the time of planned vaccination~* Subject with any abnormal laboratory results at screening~* With a history of herpangina, hand-foot-mouth disease, acute hemorrhagic conjunctivitis or acute gastrointestinal illness associated with enterovirus infection in the past 3 months~* Has been diagnosed with neurological, pulmonary, cardiovascular, hematological, hepatic or renal disorder~* With a history of hypersensitivity to vaccine or allergic disease~* Use of any investigational/non-registered product within 30 days prior to vaccination~* Use of immunoglobulins or any blood products within 3 months prior to vaccination~* Chronic administration of immunosuppressants or other immunomodulators within 5 months prior to vaccination

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- EV 71 vaccine 5ug (Type: ACTIVE_COMPARATOR): EV71 Vaccine 5ug
- EV 71 vaccine 10ug (Type: EXPERIMENTAL): EV71 vaccine 10ug

Based on this trial design, predict the completion outcome and termination type (if applicable).